Fesoterodine Fumarate Tablet, Extended Release
Product Images NDC 62332-175

Each extended-release, film-coated tablet of Fesoterodine Fumarate contains 4 mg Fesoterodine. It is recommended to store it between 20°C to 25°C (68°F to 77°F) and excursions between 15°C to 20°C (59°F to 86°F) are allowed. The package should be protected from moisture. Instructions for dosages are available in the accompanying prescribing information. The tablets should be swallowed whole and must not be chewed, divided or crushed. These tablets are manufactured by Alembic Pharmaceuticals Limited and are child-resistant. They are manufactured for Alembic Pharmaceuticals, Inc. This package contains 30 tablets and it's a prescription medicine. No additional information is available in the text obtained by .*

This is a graph (Figure 1) showing the change in the number of micturitions per 24 hours over a period of 12 weeks for a study involving three groups of participants: placebo (N=279), Fosoterodine fumarate 4mg (N=265), and Fesoterodine fumarate 8mg (N=276). The mean change from baseline is plotted on the y-axis.*

This is a graph depicting the change in the number of urge incontinence episodes per 24 hours over the course of 12 weeks, with data points at weeks 2, 8, and 12. The study compared a placebo group (N=211) to two treatment groups: one group was given Fosotorosine fumarate 4mg (N=198), and the other group was given Fesolerodine fumarate 8mg (N=223). The text "Mean change from baseline" likely refers to the average change in the number of incontinence episodes from the beginning (baseline) of the study to the end of the 12-week period.*

The text describes the mean change from baseline in the number of micturitions per 24 hours. It includes a Figure 3 showing the change in the number of micturitions per 24 hours over weeks for a study comparing a placebo group (N=266) with a group taking either Fesoterodine fumarate 4mg (N=267) or Fesoterodine fumarate 8mg (N=267).*

The text describes the mean change from baseline of urge incontinence episodes per 24 hours in a study with three groups, one receiving placebo, one receiving 4mg of fesolorodine fumarate, and one receiving 8mg of fesoterodine fumarate. The change is presented graphically in Figure 4 over the course of several weeks.*